Warning letter
Reese Pharmaceutical Company [ARCHIVED]: warning letter of May 18, 2011
FDA warning letter 160272 · Cincinnati District Office
Key facts
| Reference number | 160272 |
|---|---|
| Company | Reese Pharmaceutical Company [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | May 18, 2011 |
| Posted date | May 18, 2011 |
| Issuing office | Cincinnati District Office |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.130(c), 211.125(c), 211.125(a) |
| Inspection city | Cleveland |
| Inspection ZIP | 44106 |
| Inspection start date | Nov 3, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: